Welcome to EnVivo Pharmaceuticals

		Home \| Company \| Our Team \| Programs \| Publications \| News & Events

EnVivo is a biopharmaceutical company dedicated to discovering and developing drugs for central nervous system (CNS) disorders, currently focusing on Alzheimer’s disease, and Schizophrenia. The company’s lead programs include a Nicotinic Alpha 7 Acetylcholine Receptor Agonist Program for cognitive enhancement in Alzheimer’s disease and Schizophrenia, a Histone Deacetylase (HDAC) Inhibitor Program for cognitive enhancement in Alzheimer’s disease, a Gamma Secretase Modulator (GSM) Program for disease modifying treatment of Alzheimer’s disease and a Phosphodiesterase-10 (PDE10) Program for Schizophrenia.

EnVivo News & Events

	HONOLULU, July 14, 2010 – EnVivo Pharmaceuticals today announced at the Alzheimer’s Association 2010 International Conference on Alzheimer’s Disease (ICAD) results from its proprietary gamma-secretase modulator (GSM) pre-clinical study. In a transgenic mouse model, EnVivo’s EVP-0015962 reduced amyloid plaque build up which is believed to be a cause of Alzheimer’s disease, reversed behavioral deficits and reduced brain inflammation associated with Alzheimer’s disease.



	WATERTOWN, Mass., May 11, 2010 – EnVivo Pharmaceuticals today announced the initiation and dosing of patients in a Phase IIb study of its EVP-6124 compound, a selective alpha-7 nicotinic agonist in patients with mild to moderate Alzheimer’s disease. The multi-center, dose ranging, placebo controlled, six-month study taking place in the U.S. and Europe is designed to determine the safety and efficacy of EVP-6124 in producing procognitive effects and improving the clinical condition of Alzheimer’s disease patients.